FCCC LOGO Faculty Publications
Morgan RJ , Alvarez RD , Armstrong DK , Burger RA , Chen LM , Copeland L , Crispens MA , Gershenson DM , Gray HJ , Hakam A , Havrilesky LJ , Johnston C , Lele S , Martin L , Matulonis UA , O'Malley DM , Penson RT , Powell MA , Remmenga SW , Sabbatini P , Santoso JT , Schink JC , Teng N , Werner TL , Dwyer MA , Hughes M
Ovarian Cancer, Version 2.2013 Featured Updates to the NCCN Guidelines
Journal of the National Comprehensive Cancer Network. 2013 Oct;11(10) :1199-1209
PMID: WOS:000325929600004   
Back to previous list
Abstract
These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.
Notes
Morgan, Robert J., Jr. Alvarez, Ronald D. Armstrong, Deborah K. Burger, Robert A. Chen, Lee-may Copeland, Larry Crispens, Marta Ann Gershenson, David M. Gray, Heidi J. Hakam, Ardeshir Havrilesky, Laura J. Johnston, Carolyn Lele, Shashikant Martin, Lainie Matulonis, Ursula A. O'Malley, David M. Penson, Richard T. Powell, Matthew A. Remmenga, Steven W. Sabbatini, Paul Santoso, Joseph T. Schink, Julian C. Teng, Nelson Werner, Theresa L. Dwyer, Mary A. Hughes, Miranda